NCT05638854View on ClinicalTrials.gov

A Study to Evaluate Safety and Pharmacokinetics of ZB002 in Healthy Participants and Participants With Rheumatoid Arthritis

PHASE1RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 8, 2022

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Healthy VolunteersRheumatoid Arthritis
Interventions
DRUG

ZB002

ZB002 will be administered subcutaneously as per schedule specified in the respective arm.

DRUG

Placebo

Placebo will be administered subcutaneously as per schedule specified in the respective arm.

DRUG

ZB002

ZB002 will be administered subcutaneously as per schedule specified in the respective arm.

DRUG

Placebo

Placebo will be administered subcutaneously as per schedule specified in the respective arm.

Trial Locations (2)

Unknown

NOT_YET_RECRUITING

Veritus Research, Melbourne

RECRUITING

NZCR New Zealand Clinical Research, Christchurch

All Listed Sponsors
lead

Zenas BioPharma (USA), LLC

INDUSTRY